NCT06413992 2024-05-14
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Jiangsu HengRui Medicine Co., Ltd.